These results indicated that CK2 inhibitors can effectively improve the exhaustion of CD8+ T cells, enhance the function of CD8+ T cells, and significantly enhance the efficacy of anti‐PD‐1 therapy in NSCLC. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.